Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.

Conclusion: In our patients with SLE, belimumab decreased disease activity and allowed tapering of the daily glucocorticoid dose with a good safety profile.
PMID: 31264525 [PubMed - as supplied by publisher]

Source: Scandinavian Journal of Rheumatology - July 1, 2019 Category: Rheumatology Authors: Anjo C, Mascaró JM, Espinosa G, Cervera R Tags: Scand J Rheumatol Source Type: research